STEM CELLS USED FOR AGE-RELATED MACULAR DEGENERATION
Dr Jenna Hall
Senior Research Associate
University of Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2025
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
Dr Hall was awarded a highly competitive and sought after Australian Research Council Centre for Personalised Therapeutics and Technologies (ARC CPTT) scholarship which, in addition to funding her PhD, included an industry internship with a leading life sciences consultancy firm. Her internship with Biointelect allowed her to contribute to strategic projects addressing key challenges in Australia’s biotechnology ecosystem. Her white papers on the country’s vaccine and drug value chain, as well as anti-obesity medication, demonstrated her ability to combine scientific knowledge with commercial insights to influence policy and improve pandemic preparedness.
Dr Hall has over four years of industry experience, including her time at the New York Stem Cell Foundation, where she collaborated with engineers and data scientists to develop scalable workflows for cell reprogramming, downstream differentiation, and automated maintenance. For her next career step, Dr Hall is hoping to secure a role in a fertility research lab.
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Impact of Leukaemia Foundation’s Research Funding into Blood Cancer
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
